RE:CBCWell said Nutrader. Yesterday I presented an overview of the only other rapid, point of care test authorized by HC. I just looked again and there is now a third one as of February 10, 2021. Produced by Sd Biosensor it still has the drawback of requiring a nasopharyngeal sample although Roche (distributing it) claims there is an updated version that requires a less invasive nasal swab. It has 86% overall sensitivity. All of these are on the FDA site as well and like here in Canada NONE of them are being used on a mass scale for a host of reasons.
The 86% overall sensitivity has already been reached by SCV2, it has a 100% sensitivity for high viral loads ......and as the date of this most recent authorization by HC is still in the mix ....and at the forefront if you consider it requires a SALIVA sample.
In spite of the musings of shorters and penny flippers Morningstar's Fair Value sp is $.62 BEFORE news and their speculative 1-star valuation is at $4.18 with a solid revenue generating NR. The resistance points are at $.47, $495 and $.52 this morning and Barchart still has an 88% Strong Buy.
Thrm and SCV2 is being played with at the moment but the only place it's going over the next few weeks is up.
GLTA those patient to be long.